The federal drug pricing program 340B helps hospitals and clinics in Virginia and across the nation care for underserved patients by requiring pharmaceutical companies to offer prescription discounts ...

A fight over an embattled drug discount program is intensifying on Capitol Hill, as lawmakers weigh competing proposals to ...

The 340B Drug Pricing Program may be partly driving U.S. hospital consolidation and worsening affordability for patients, ...

Outpatient drug purchases under the 340B Drug Pricing Program crossed the $100 billion mark across 2025, a roughly 23% ...

“When a program designed to deliver targeted assistance drives up system-wide costs, reform is no longer optional,” says health expert Sally Pipes. “It's necessary.” If a charity organization ...

Forbes contributors publish independent expert analyses and insights. Anthony T. Lo Sasso is Professor of Public Affairs at UW-Madison This voice experience is generated by AI. Learn more. This voice ...

Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the Health, Education, Labor and Pensions Committee appear to agree that ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

The Government Accountability Office believes Congress should slash the financial incentives the government pays hospitals in the 340B drug program, it said in a new report, over concerns that ...

Unexpected windfall or fragile safety net? Affluent communities or vulnerable poor? Welfare check or supplemental provider program? Making sense of the latest 340B program study published by the ...

AHA responds to Information Collection Request about the Health Resources and Services Administration’s proposed 340B Rebate Model Program.